Part D not immune to fraud
Executive Summary
Identifying fraud in the Medicare prescription drug program may be difficult relative to other government programs due to a lack of transparency in the market, witnesses at a House Committee on Oversight and Government Reform hearing on pharmaceutical waste, fraud and abuse suggest. The Feb. 9 hearing also addresses fraud and abuse related to Medicaid pricing and the 340B program. Waxman indicates that issues such as the susceptibility of Part D to fraud and the limitations of enforcement efforts to effectively litigate violations will be an integral part of the committee's investigative priorities for the next two years...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.